Table 3.
Multivariable hazard ratios for the outcome discontinuation of lipid lowering therapy among children ages 8 to 20 with at least 12 months of follow up after their index dispensing - whole population and subpopulation of patients with diagnosis of dyslipidemia prior to the index dispensing
| Total Population (n=8,710) |
Population with a dyslipidemia dianosis (n=2,211) |
|||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | P-value | Hazard Ratio | 95% CI | P-value | |
| Demographics | ||||||
| Female | 1.03 | (0.98–1.08) | 0.26 | 0.89 | (0.80–0.99) | 0.03 |
| Age ≥15 | 1.06 | (1.01–1.13) | 0.03 | 1.21 | (1.07–1.38) | 0.00 |
| Index LLT | ||||||
| Non-statin | Ref | -- | -- | Ref | -- | -- |
| statin | 0.66 | (0.63–0.69) | <.0001 | 0.76 | (0.68–0.84) | <.0001 |
| Statin Combination | 0.46 | (0.40–0.52) | <.0001 | 0.36 | (0.27–0.47) | <.0001 |
| Non-Statin Combination | 0.86 | (0.53–1.38) | 0.52 | 1.02 | (0.51–2.07) | 0.95 |
| Diagnosed conditions | ||||||
| Dyslipidemia | 0.61 | (0.57–0.65) | <.0001 | -- | -- | -- |
| Obesity | 0.99 | (0.88–1.13) | 0.92 | 1.23 | (1.02–1.49) | 0.03 |
| Hypertension | 1.02 | (0.91–1.13) | 0.76 | 1.15 | (0.95–1.39) | 0.16 |
| Metabolic Syndrome | 0.92 | (0.76–1.12) | 0.40 | 0.99 | (0.74–1.32) | 0.92 |
| Diabetes | 1.02 | (0.92–1.14) | 0.69 | 1.12 | (0.92–1.37) | 0.27 |
| Asthma | 1.07 | (0.98–1.16) | 0.16 | 1.04 | (0.85–1.27) | 0.72 |
| Chronic Kidney Disease | 0.69 | (0.54–0.88) | 0.00 | 0.85 | (0.47–1.52) | 0.57 |
| Depression | 1.08 | (0.96–1.21) | 0.19 | 1.12 | (0.88–1.42) | 0.37 |
| ADHD | 0.93 | (0.83–1.05) | 0.24 | 0.81 | (0.64–1.03) | 0.08 |
| Medications dispensed* | ||||||
| Anti-Hypertensive | 0.90 | (0.85–0.96) | 0.00 | 0.83 | (0.72–0.97) | 0.02 |
| Anti-Asthmatic | 0.99 | (0.94–1.04) | 0.75 | 0.94 | (0.84–1.05) | 0.25 |
| Anti-Diabetic | 0.95 | (0.86–1.04) | 0.24 | 1.11 | (0.92–1.34) | 0.29 |
| Anti-Depressant | 0.96 | (0.90–1.02) | 0.16 | 0.99 | (0.86–1.14) | 0.87 |
| Anti-Psychotic | 0.89 | (0.79–0.99) | 0.03 | 0.82 | (0.64–1.03) | 0.09 |
| Procedures* | ||||||
| Diabetes screening | 0.96 | (0.90–1.02) | 0.17 | 0.97 | (0.86–1.09) | 0.59 |
| Lipid panel | 0.66 | (0.62–0.69) | <.0001 | 0.59 | (0.51–0.67) | <.0001 |
| Health Care Utilization* | ||||||
| Outpatient visits | ||||||
| 0 | Ref | -- | Ref | -- | ||
| 1–3 | 0.96 | (0.86–1.08) | 0.52 | 0.84 | (0.45–1.54) | 0.56 |
| 4–5 | 0.93 | (0.82–1.05) | 0.23 | 0.91 | (0.49–1.67) | 0.75 |
| ≥6 | 0.87 | (0.77–0.98) | 0.02 | 0.87 | (0.47–1.58) | 0.64 |
| Inpatient Visits | ||||||
| 0 | Ref | -- | Ref | -- | ||
| 1–2 | 1.02 | (0.93–1.10) | 0.72 | 1.01 | (0.80–1.27) | 0.96 |
| ≥3 | 0.83 | (0.70–0.97) | 0.02 | 1.11 | (0.67–1.84) | 0.68 |
| Drug Dispensing | ||||||
| 0 | Ref | -- | Ref | -- | ||
| 1–2 | 1.07 | (0.96–1.20) | 0.21 | 1.00 | (0.82–1.23) | 0.98 |
| ≥3 | 1.13 | (1.02–1.25) | 0.02 | 1.06 | (0.88–1.28) | 0.51 |
*
In the 12 months prior to index dispensing